13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001274413
Total reported value
$143.3M
$143.3M
74 檔
26.9%
According to the latest 13F quarterly dataset, Sectoral Asset Management Inc managed an equity portfolio of $143.3M at the end of Q4 2025, spanning 74 distinct U.S. exchange-listed positions.
In Q4 2025, Sectoral Asset Management Inc adopted a defensive or profit-taking posture, trimming 44 positions and completely liquidating 14 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | EVMN | Evommune Inc | Stock-Other | 8.08% | -11.22% | EXIT | |
| 2 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 7.34% | +0.45% | — | |
| 3 | LLY | Eli Lilly & Co | Stock-Healthcare | 6.27% | +0.48% | -22.40% | |
| 4 | SI | Shoulder Innovations Inc | Stock-Other | 5.64% | +0.91% | +14.44% | |
| 5 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 3.60% | +0.49% | +0.37% | |
| 6 | AMGN | Amgen Inc | Stock-Healthcare | 3.43% | -0.58% | +26.40% | |
| 7 | JNJ | Johnson & Johnson | Stock-Healthcare | 3.37% | -0.46% | +32.68% | |
| 8 | ABBV | Abbvie Inc | Stock-Healthcare | 3.08% | -0.06% | +13.51% | |
| 9 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 2.91% | -0.98% | +3.76% | |
| 10 | ABT | Abbott Laboratories | Stock-Healthcare | 2.36% | -1.04% | +36.63% | |
| 11 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 2.30% | -1.12% | -6.38% | |
| 12 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.20% | -0.38% | -15.65% | |
| 13 | BSX | Boston Scientific CORP | Stock-Healthcare | 2.11% | -0.73% | +24.86% | |
| 14 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.95% | -0.44% | -25.60% | |
| 15 | DHR | Danaher CORP | Stock-Healthcare | 1.94% | -0.23% | — | |
| 16 | SYK | Stryker CORP | Stock-Healthcare | 1.85% | -0.03% | +52.33% | |
| 17 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.81% | -0.20% | — | |
| 18 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.81% | -0.20% | +30.49% | |
| 19 | GILD | Gilead Sciences Inc | Stock-Healthcare | 1.76% | -1.60% | -8.52% | |
| 20 | INSM | Insmed Inc | Stock-Healthcare | 1.56% | -1.07% | -16.71% | |
| 21 | DXCM | Dexcom Inc | Stock-Healthcare | 1.53% | +1.18% | +38.65% | |
| 22 | VERA | Vera Therapeutics Inc | Stock-Other | 1.50% | -0.13% | +22.09% | |
| 23 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.33% | -0.43% | -89.24% | |
| 24 | BNTX | Biontech Se-adr | Stock-Other | 1.31% | +1.03% | -2.50% | |
| 25 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.18% | -0.21% | +15.00% | |
| 26 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 1.12% | — | -18.76% | |
| 27 | SMMT | Summit Therapeutics Inc | Stock-Other | 1.12% | +1.08% | +7.50% | |
| 28 | RCUS | Arcus Biosciences Inc | Stock-Other | 1.09% | +1.53% | -84.53% | |
| 29 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.03% | -0.41% | -22.95% | |
| 30 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.97% | -0.13% | -19.91% | |
| 31 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.95% | -0.23% | -8.65% | |
| 32 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.95% | -0.69% | EXIT | |
| 33 | COGT | Cogent Biosciences Inc | Stock-Other | 0.93% | -0.03% | — | |
| 34 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.92% | -0.47% | -6.67% | |
| 35 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.85% | +0.07% | -20.48% | |
| 36 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.79% | +0.67% | -9.32% | |
| 37 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.71% | +1.18% | -78.08% | |
| 38 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.70% | — | -91.24% | |
| 39 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.68% | -0.36% | -18.17% | |
| 40 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.67% | -0.43% | +125.23% | |
| 41 | BOLD | Boundless Bio Inc | Stock-Other | 0.65% | -0.62% | EXIT | |
| 42 | ONC | Beone Medicines Ltd-adr | Stock-Other | 0.65% | -0.15% | -62.99% | |
| 43 | RDNT | Radnet Inc | Stock-Healthcare | 0.63% | -0.37% | EXIT | |
| 44 | AVBP | Arrivent Biopharma Inc | Stock-Other | 0.62% | +1.32% | -2.50% | |
| 45 | QURE | uniQure N.V. | Stock-Other | 0.59% | -0.41% | EXIT | |
| 46 | ASND | Ascendis Pharma A/S | Stock-Other | 0.56% | -0.60% | EXIT | |
| 47 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.55% | — | — | |
| 48 | PFE | Pfizer Inc | Stock-Healthcare | 0.54% | -0.18% | -64.81% | |
| 49 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 0.53% | -0.31% | EXIT | |
| 50 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.53% | -0.11% | -9.13% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SI | Shoulder Innovations Inc | +2.3% | +14.44% | Add |
| 2 | LLY | Eli Lilly & Co | +1.9% | -22.40% | Trim |
| 3 | AMGN | Amgen Inc | +1.6% | +26.40% | Add |
| 4 | JNJ | Johnson & Johnson | +1.6% | +32.68% | Add |
| 5 | CTNM | Contineum Therapeutics Inc-a | +1.5% | — | Unchanged |
| 6 | VRTX | Vertex Pharmaceuticals Inc | +1.1% | +3.76% | Add |
| 7 | VERA | Vera Therapeutics Inc | +1% | +22.09% | Add |
| 8 | ABBV | Abbvie Inc | +1% | +13.51% | Add |
| 9 | MRK | Merck & Co. Inc. | +1% | +30.49% | Add |
| 10 | ABT | Abbott Laboratories | +0.9% | +36.63% | Add |
| 11 | REGN | Regeneron Pharmaceuticals | +0.9% | -6.38% | Trim |
| 12 | SYK | Stryker CORP | +0.9% | +52.33% | Add |
| 13 | BSX | Boston Scientific CORP | +0.8% | +24.86% | Add |
| 14 | UNH | Unitedhealth Group Inc | +0.7% | +0.37% | Add |
| 15 | DXCM | Dexcom Inc | +0.7% | +38.65% | Add |
| 16 | TMO | Thermo Fisher Scientific Inc | +0.6% | — | Unchanged |
| 17 | DHR | Danaher CORP | +0.6% | — | Unchanged |
| 18 | ISRG | Intuitive Surgical Inc | +0.6% | -15.65% | Trim |
| 19 | UTHR | United Therapeutics CORP | +0.5% | +125.23% | Add |
| 20 | EW | Edwards Lifesciences CORP | +0.5% | +15.00% | Add |
| 21 | GILD | Gilead Sciences Inc | +0.4% | -8.52% | Trim |
| 22 | INSM | Insmed Inc | +0.4% | -16.71% | Trim |
| 23 | ROIV | Roivant Sciences Ltd. | +0.3% | -9.32% | Trim |
| 24 | TARS | Tarsus Pharmaceuticals Inc | +0.3% | -19.91% | Trim |
| 25 | SNDX | Syndax Pharmaceuticals Inc | +0.3% | -22.95% | Trim |
| 26 | TRVI | Trevi Therapeutics Inc | +0.3% | -20.48% | Trim |
| 27 | BBIO | Bridgebio Pharma Inc | +0.2% | -18.17% | Trim |
| 28 | BNTX | Biontech Se-adr | +0.2% | -2.50% | Trim |
| 29 | AZNN | Astrazeneca Plc-spons Adr | +0.2% | -18.76% | Trim |
| 30 | HNGE | Hinge Health Inc-a | +0.2% | +26.77% | Add |
| 31 | ARGX | Argenx Se - Adr | +0.2% | -25.60% | Trim |
| 32 | SMMT | Summit Therapeutics Inc | +0.2% | +7.50% | Add |
| 33 | AXSM | Axsome Therapeutics Inc | +0.2% | +70.59% | Add |
| 34 | AVBP | Arrivent Biopharma Inc | +0.2% | -2.50% | Trim |
| 35 | IONS | Ionis Pharmaceuticals Inc | +0.2% | -9.13% | Trim |
| 36 | RDNT | Radnet Inc | +0.2% | +10.00% | Add |
| 37 | RAPP | Rapport Therapeutics Inc | +0.2% | -10.48% | Trim |
| 38 | PTCT | Ptc Therapeutics Inc | +0.2% | -9.61% | Trim |
| 39 | MLYS | Mineralys Therapeutics Inc | +0.1% | -6.67% | Trim |
| 40 | BOLD | Boundless Bio Inc | +0.1% | — | Unchanged |
| 41 | ASND | Ascendis Pharma A/S | +0.1% | -9.64% | Trim |
| 42 | ILMN | Illumina Inc | +0.1% | -9.35% | Trim |
| 43 | JAZZ | Jazz Pharmaceuticals plc | +0.1% | -8.69% | Trim |
| 44 | BIIB | Biogen Inc | +0.1% | -9.26% | Trim |
| 45 | OMDA | Omada Health Inc | +0.1% | +32.73% | Add |
| 46 | INCY | Incyte CORP | +0.1% | -9.24% | Trim |
| 47 | RPRX | Royalty Pharma plc | +0.1% | -8.73% | Trim |
| 48 | NBIX | Neurocrine Biosciences Inc | 0% | -9.63% | Trim |
| 49 | ALNY | Alnylam Pharmaceuticals Inc | 0% | -8.65% | Trim |
| 50 | MRNA | Moderna Inc | 0% | -10.63% | Trim |
According to official SEC Form 13F filings, Sectoral Asset Management Inc reported a total U.S. public equity portfolio value of $143.3M across 74 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including EVMN, CTNM, LLY) accounted for 26.9% of total reported equity market value during Q4 2025.
Top New Position Initiated
EVMN
市值: $10.1M
Top Position Liquidated / Trimmed
ANAB
前期市值: $6.0M
During Q4 2025, Sectoral Asset Management Inc's top holdings by market value included EVMN (8.1%)、CTNM (7.3%)、LLY (6.3%). The largest single position, EVMN, represented 8.1% of total portfolio value.
In Q4 2025, Sectoral Asset Management Inc made 84 total portfolio adjustments, initiating 6 new buys, adding to 20 positions, trimming 44 holdings, and fully liquidating 14 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.